Table 2.
Ocular control of adalimumab (ADA) therapy, overall and stratified according to the concomitant use of DMARDs.
| Observed | 6 months | 12 months | >12 months | |
|---|---|---|---|---|
| Overall, N (%) | ||||
| N. obs. | 106 | 92 | 78 | 55 |
| Ocular control | — | 77 (83.7) | 65 (83.3) | 52 (94.6) |
| No ocular control | — | 15 (16.3) | 13 (16.7) | 3 (5.5) |
|
| ||||
| Stratified according to reason for ADA beginning: | ||||
| Ocular (+/- systemic) | ||||
| N. obs. | 76 | 65 | 56 | 36 |
| Ocular control | — | 54 (83.1) | 45 (80.4) | 33 (91.7) |
| Systemic | ||||
| N. observed | 30 | 27 | 27 | 19 |
| Ocular control | — | 23 (85.2) | 23 (90.9) | 19 (100.0) |
|
| ||||
| Stratified according to DMARD cotreatment in the first year: | ||||
| Only ADA group, N (%) | ||||
| N. obs. | 29 | 25 | 20 | 18 |
| Ocular control | 22 (88.0) | 17 (85.0) | 17 (94.4) | |
| ADA+DMARD group, N (%) | ||||
| N. obs. | 29 | 29 | 25 | 13 |
| Ocular control | 21 (72.4) | 19 (76.0) | 13 (100.0) | |
| p value∗ | 0.191 | 0.709 | n.c. | |
∗ p value from the comparison of proportions of ocular control in the “only ADA” vs. “ADA+DMARD” groups; ADA: adalimumab; DMARDs: disease-modifying antirheumatic drugs; n.c.: not calculable.